Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Phase 2EIK1001pembrolizumabPositive

AI Analysis

Summary

Eikon Therapeutics announced the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy as first-line therapy for stage 4 NSCLC.

Clinical Trial Data

Phase

2/3

Importance:6/10

Sentiment:

0.60

registrational trialPhase 2/3NSCLCfirst patient dosedcombination therapy

Related Companies

$EIKN

Read the original article

Published by GlobeNewswire Clinical Studies on July 27, 2026 11:30 AM

Read Original